Picture of HALEON logo

HLN HALEON News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

REG - Haleon PLC - Completion of off-market purchase and Total Voting

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241003:nRSC8611Ga&default-theme=true

RNS Number : 8611G  Haleon PLC  03 October 2024

 

Haleon plc: Completion of off-market purchase and Total Voting Rights and
Capital

 

3 October 2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today
announces that it has completed the off-market purchase of 60,526,315 ordinary
shares of £0.01 each, repurchased from Pfizer Inc. ("Pfizer") for an
aggregate purchase price of £230 million.

The off-market purchase includes (i) 30,161,278 ordinary shares which Haleon
has cancelled and (ii) 30,365,037 ordinary shares which will be held as
treasury shares.

As at 3 October 2024, the total number of ordinary shares issued by Haleon is
9,083,725,919, of which 30,365,037 are held as treasury shares. Therefore, the
number of ordinary shares with voting rights is 9,053,360,882 and this figure
may be used by shareholders (and others with notification obligations) as the
denominator for the calculation by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

Amanda Mellor

Company Secretary

 

 

Enquiries

 

 Investors                                    Media

 Sonya Ghobrial          +44 7392 784784      Zoë Bird            +44 7736 746167
 Rakesh Patel            +44 7552 484646      Gemma Thomas        +44 7985 175048
 Emma White              +44 7823 523562

 Email: investor-relations@haleon.com         Email: corporate.media@haleon.com

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans five major categories - Oral Health, Pain Relief, Respiratory Health,
Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its
long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu,
Otrivin, Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.

 

For more information please visit www.haleon.com (http://www.haleon.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCMJBBTMTMMBBI

Recent news on HALEON

See all news